PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
121.05%
Some net income increase while TRVN is negative at -22.64%. John Neff would see a short-term edge over the struggling competitor.
473.10%
Some D&A expansion while TRVN is negative at -65.70%. John Neff would see competitor’s short-term profit advantage unless expansions here deliver big returns.
20.60%
Deferred tax of 20.60% while TRVN is zero at 0.00%. Bruce Berkowitz would see a partial difference that can matter for future cash flow if large in magnitude.
-20.60%
Negative yoy SBC while TRVN is 26.73%. Joel Greenblatt would see less immediate dilution advantage if talent levels remain strong.
534.15%
Slight usage while TRVN is negative at -56.44%. John Neff would note competitor possibly capturing more free cash unless expansions are needed here.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
82.02%
A yoy AP increase while TRVN is negative at -100.00%. John Neff would see competitor possibly improving relationships or liquidity more rapidly.
107.35%
Growth well above TRVN's 119.65%. Michael Burry would see a potential hidden liquidity or overhead issue overshadowing competitor's approach.
-145.76%
Negative yoy while TRVN is 100.59%. Joel Greenblatt would see a near-term net income or CFO stability advantage unless competitor invests or writes down more aggressively.
-3.22%
Both yoy CFO lines are negative, with TRVN at -56.29%. Martin Whitman would suspect cyclical or cost factors harming the entire niche’s cash generation.
-7359.68%
Both yoy lines negative, with TRVN at -727.40%. Martin Whitman would suspect a cyclical or broad capital spending slowdown in the niche.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Growth of 100.00% while TRVN is zero at 0.00%. Bruce Berkowitz sees a moderate difference requiring justification by ROI in these smaller invests.
-7359.68%
Both yoy lines negative, with TRVN at -727.40%. Martin Whitman suspects a broader cyclical shift away from heavy investing across the niche.
37.62%
Debt repayment growth of 37.62% while TRVN is zero at 0.00%. Bruce Berkowitz sees a mild advantage that can reduce interest costs unless expansions demand capital here.
299.00%
We slightly raise equity while TRVN is negative at -100.03%. John Neff sees competitor possibly preserving share count or buying back shares.
No Data
No Data available this quarter, please select a different quarter.